The Impact of Physician Prescribing Habits and Payer Reimbursement on the Pulmonary Arterial Hypertension Drug Market

— A Webinar from Decision Resources

Based on our Physician & Payer Forum report entitled Pulmonary Arterial Hypertension: How Will Physicians and Payers Shape an Evolving Market? Decision Resources is offering an exclusive webinar entitled The Impact of Physician Prescribing Habits and Payer Reimbursement on the Pulmonary Arterial Hypertension Drug Market. Because this webinar will feature major report findings, it is ONLY available to purchasers of this report.

Please contact us to learn how you can purchase this Physician & Payer Forum report and attend the webinar.

Despite being a rare disease, pulmonary arterial hypertension (PAH) offers sizeable untapped potential for drug developers and the opportunity for billion-dollar worldwide sales, as already achieved in this market by Actelion’s Tracleer. Three new drugs, Gilead’s Letairis and United Therapeutics’ Tyvaso and Adcirca, have received FDA approval in the last three years, but while prescribers now have more treatment options for this life-threatening disease, no drug or drug combination provides a panacea and all agents have limitations that restrict their use. The remaining high unmet need in the treatment of PAH signals the opportunities for new disease-modifying therapies. Historically the domain of specialty pharma and small biotech firms, the PAH market has now drawn the attention of bigger players. With increasing diagnosis and polypharmacy rates set to further grow the PAH market, treatment options in this space are potentially lucrative prospects.

This webinar, presented by Decision Resources Director Mary Fletcher-Louis, will answer the following questions:

• What percentage of PAH patients receives monotherapy versus combination therapy, and what is the patient share for available PAH therapies? What has been the market penetration of the recently launched agents Adcirca and Tyvaso, and in which line of therapy are they most often used? How does drug usage vary between pulmonologists in specialized PAH centers versus pulmonologists who practice outside of these centers?
• What factors influence the prescribing of PAH treatments? Which attributes of each marketed drug are pulmonologists most and least satisfied with? Are these the same attributes that influence MCO pharmacy directors, in terms of preferential formulary placement of PAH drugs?
• What are the attitudes of MCO pharmacy directors and pulmonologists regarding Pfizer’s Thelin, Novartis’s imatinib, and Bayer’s riociguat? What share of the PAH market can these drugs expect to capture, and in which lines of therapy? What features of these drugs are likely to drive and constrain prescribing?
• How do MCOs monitor and restrict PAH treatment? How is monotherapy and combination PAH therapy viewed by plans? Are tier placements for PAH treatments expected to change over the next 12 months? Do MCO pharmacy directors penalize second-in-class drugs?
• At what stage of the disease are patients diagnosed? What are the treatment rates at different stages of PAH? How has the rate of referral to a PAH center prior to initial treatment changed in the last 12 months?

Ms. Fletcher-Louis will conduct a live Q & A session after the presentation.

Registration

The Impact of Physician Prescribing Habits and Payer Reimbursement on the Pulmonary Arterial Hypertension Drug Market

June 30, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase this Physician & Payer Forum report and attend the webinar, please contact us using the information below.

Contact Us

In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2010 Decision Resources, Inc. All rights reserved.